3-Methoxypyrrolidine-1-carbonyl chloride | 1214285-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-Methoxypyrrolidine-1-carbonyl chloride
• CAS: 1214285-45-6
• 化学式: C₆H₁₀ClNO₂
• 分子量: 163.6
• InChiKey: OOCJQEKBFZXKFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10174028B2

  公开（公告）日：2019-01-08

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供的是通式 I 的化合物： 及其立体异构体和药学上可接受的盐或溶液，其中 A、B、D、E、X1、X2、X3 和 X4 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可以用 RET 激酶抑制剂治疗的疾病，包括由 RET 激酶介导的疾病或紊乱。
• Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10174027B2

  公开（公告）日：2019-01-08

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供的是通式 I 的化合物： 及其立体异构体和药学上可接受的盐或溶液，其中 A、B、D、E、X1、X2、X3 和 X4 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可以用 RET 激酶抑制剂治疗的疾病，包括由 RET 激酶介导的疾病或紊乱。
• SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
  申请人：Array BioPharma, Inc.

  公开号：US20180179203A1

  公开（公告）日：2018-06-28

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3 and X 4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.